Navigation Links
Study Sheds Light on Value of Newer Antipsychotic Drugs for Schizophrenia

A study comparing medications for schizophrenia found two of three newer antipsychotic drugs are more effective in patients// who did not benefit from an older medication, according to a research.

The study is one of the latest stemming from the longstanding Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE). Dr. Scott Stroup, associate professor of psychiatry in the UNC School of Medicine, is the lead author.

In the original CATIE study, 257 patients were initially selected randomly to take the older antipsychotic drug perphenazine. Of these, 192 discontinued the medication for various reasons, including ineffectiveness and intolerable side effects. Among those who discontinued, 114 agreed to be randomly chosen to take one of three newer antipsychotic medications – olanzapine, quetiapine or risperidone.

In the current study, Stroup and colleagues compared the effectiveness of the medications by determining how long patients stayed on their assigned medication. Those taking quetiapine stayed on the longest — averaging about 10 months before stopping. Those taking olanzapine discontinued after an average of about seven months, and those taking risperidone discontinued after an average of four months.

Although the discontinuation results suggest that olanzapine was generally on par with quetiapine, patients taking olanzapine had more weight- and metabolic-related side effects than those on the other medications. While none of those patients taking quetiapine discontinued use due to weight gain or metabolic side effects, 13 percent of those assigned to olanzapine discontinued it due to weight gain or metabolic problems and 5 percent of those on risperidone did so.

“The results favor quetiapine and, to an extent, olanzapine,” Stroup said. “These findings diverge somewhat from other CATIE studies in which second generation medications are compared, but overall there is consistency.”


'"/>




Page: 1 2

Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer

Post Your Comments:
(Date:11/27/2009)..., , NEUILLY-SUR-SEINE, France, Nov. 27 /...merican professional cycling team dedicated to eth...f cycling champions, announced today that it will ...f Transitions Optical as a new sponsor of the team...acturer of adaptive eyewear, offering the most adv...
(Date:11/27/2009)...Soaring rates to bring unprecedented medical, econ... Nov. 27 (HealthDay News) -- The number of people ...double over the next 25 years, a new study predict...t 44.1 million people with the disease, up from 23... of treating people with diabetes will triple, the...
(Date:11/27/2009)... Specialist manufacturers...products are saving millions of dollars by bringin...n process. Increasing numbers of pro-active medica...xperts at the concept stage of their projects, ens...sting design processes or potentially outdated tec...
(Date:11/26/2009)... In the next 25 years, the number of Americans li...from 23.7 million in 2009 to 44.1 million in 2034....lmost triple, rising from $113 billion to $336 bil...besity, researchers based at the University of Chi...e . , The number of those with diabetes covered ...
(Date:11/26/2009)... No more letters from the...r,personalized text messages from Santa , ...ffort to increase operational efficiencies at the ...g to help keep children all over the globe informe...,Elves in Santa’s research department have i...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...than 46 million,people -- one in five adults -- in...diagnosed arthritis.(1) Many of these adults also ...nges when changing their hearing aid,battery. Dura...s recognized the Duracell EasyTab(R) hearing aid b...
... hospital,is crowded on admission day, children ma...ss complicated illnesses that require ongoing asse...ease. Hospital crowding does not,affect the length...during a period of increased workload,hospital car...
...levels are considered to be a risk factor for card...ny cholesterol lowering drugs have been developed ...lass of these drugs, statins, has been found to re...of Alzheimers Disease, Amalia Dolga and co-workers...
... of the worlds leading heart stem cell experts, wi... Anne McLaren in the keynote lecture of the inaugu...in Edinburgh. Dr McLaren was an early pioneer of t...from the Netherlands is a leading expert in the st...
...psychologist at the University of Liverpool is hel...ative care service for heart patients in Bermuda. ...h the Bermuda Heart Foundation, will help support ...art attacks. If the heart rhythm increases in spee...
...evices and research for mechanical circulatory sup... Health (NIH) National Heart, Lung, and Blood Inst...m will be discussed at the International Society f...Place and Hynes Convention Center. , The use o...
Other Medicine News:Health News:Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery 2Health News:Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery 3Health News:Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery 4Health News:Admission-Day Crowding May Increase Hospital Stay for Children With Less Complicated Illnesses 2Health News:Heart stem cell scientist to honor pioneering woman scientist in keynote speech 2Health News:Psychologist develops post-operative care for heart patients in Bermuda 2Health News:New research for mechanical support devices in pediatrics to be released at ISHLT 2
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...ry-USMarketTrends&Analysis http://www.reportl...arket-Trends--Analysis.html ,, TheUSintranasal...uticapplicationsfromthedeliveryofconventionallocal...drugs.Thefutureofthetechnologyhingesontotheeffecti...
(Date:11/25/2009)... Nov. 25 HeartWare Inter...ng innovator and provider of less invasive, miniat...izing the treatment of advanced heart failure, tod...tor presentation at the 21st Annual Piper Jaffray ..., December 2, 2009. The conference is being held a...
(Date:11/24/2009)... /PRNewswire-Asia/ -- Chindex International, Inc.,...t American provider of Western,healthcare products...oday,announced that the Company will attend the 21...nference, to be held December 1 - 2, 2009, at the,...rrently scheduled to present at 11:30 am ET on Tue...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2Chindex International to Present at Piper Jaffray Health Care Conference 2Beth Shulte joins Navvis 26amp 3B Company 54009 1Beth Shulte joins Navvis 26amp 3B Company 54009 2Young early stage ovarian cancer patients can preserve fertility 54007 1Young early stage ovarian cancer patients can preserve fertility 54007 2WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 13461 1WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting 13461 2
...al trial to study Prasugrel against Clopidogrel...IANAPOLIS, June 23 Daiichi,Sankyo Company, Limite...Y ),said that the U.S. Food and Drug Administratio...sugrel new drug application (NDA) based on,supplem...d. This three,month extension allows the FDA time ...
...ignificantly higher inciden... Therapeutics,Inc. (Nasdaq: CVTX ) today announce... results of a major study demonstrating that one i... year after a myocardial infarction (MI),or heart ...ignificantly,elevated rates of depression among ca...
Other Medicine Technology:FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel 2FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel 3FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel 4CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year 2CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year 3CV Therapeutics Announces Archives of Internal Medicine Publication of Study Showing 20 Percent of Heart Attack Patients in Premier Registry Experienced Angina at One Year 4
Kratz-Barraquer Eye Speculum - Pediatric
Kratz-Nichamin Speculum
Barraquer Eye Speculum
Wiener Eye Speculum
Medicine Products: